Skip to main content
Retour
Watch Compare

NEUROONE MEDICAL TECHNOLOGIES Corp

Qualité des données : 100%
NMTC
Nasdaq Manufacturing Measuring & Analyzing Instruments
0,73 €
▼ 0,01 € (-0,75%)
Cap. Boursière: 37,39 M
Prix
0,74 €
Cap. Boursière
37,39 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Revenue grew 167,32% annually over 5 years — strong growth
Negative free cash flow of -6,28 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 3,85%
Capital efficient — spends only 1,41% of revenue on capex

Croissance

Revenue Growth (5Y)
167,32%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)163,47%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-93,67%
En dessous de la moyenne du secteur (-53,53%)
ROIC-72,27%
Net Margin-78,34%
Op. Margin-87,71%

Sécurité

Debt / Equity
N/A
Current Ratio6,41
Interest CoverageN/A

Valorisation

PE (TTM)
-5,48
En dessous de la moyenne du secteur (-1,48)
P/B Ratio5,84
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1366 pairs)
Métrique Action Médiane du Secteur
P/E -5,5 -1,5
P/B 5,8 1,6
ROE % -93,7 -53,5
Net Margin % -78,3 -41,5
Rev Growth 5Y % 167,3 1,8
D/E — 0,3

Objectif de Cours des Analystes

3 analystes
Buy
Actuel
0,73 €
+177.8%
Objectif
2,03 €
1,50 €
1,60 €
3,00 €
Prévisions
BPA Prévisionnel -0,08 €
CA Est. 15,12 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2027 -0,08 €
-0,12 € – -0,05 €
 15,12 M 3
FY2026 -0,12 €
-0,16 € – -0,09 €
 11,46 M 3

Surprises de Résultats

Derniers 5 trimestres
Trimestre BPA Est. BPA Réel Surprise
Q42025 -0,04 € -0,03 € +25,0%
Q32025 -0,04 € -0,04 € 0,0%
2026-Q1 -0,04 € -0,03 € +18,3%
Q22025 -0,05 € -0,03 € +40,0%
Q12025 -0,09 € -0,07 € +22,2%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 163,47% Revenue Growth (3Y) 115,86%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 167,32% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 8,72 M Net Income (TTM) -6,83 M
ROE -93,67% ROA -70,41%
Gross Margin 54,87% Operating Margin -87,71%
Net Margin -78,34% Free Cash Flow (TTM) -6,28 M
ROIC -72,27% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 6,41
Interest Coverage N/A Asset Turnover 0,90
Working Capital 6,81 M Tangible Book Value 6,36 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -5,48 Forward P/E N/A
P/B Ratio 5,84 P/S Ratio 4,29
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -16,81%
Market Cap 37,39 M Enterprise Value 33,83 M
Per Share
EPS (Diluted TTM) -0,18 Revenue / Share 0,17
FCF / Share -0,12 OCF / Share -0,12
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1,41% FCF Conversion 92,02%
SBC-Adj. FCF -7,55 M Growth Momentum -3,85

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 9,10 M 3,45 M 1,95 M 171 169,0 178 146,0
Net Income -3,61 M -12,32 M -11,86 M -10,00 M -9,95 M
EPS (Diluted) -0,09 -0,46 -0,65 -0,63 —
Gross Profit 5,14 M 1,08 M 456 517,0 -70 794,0 -97 749,0
Operating Income -4,23 M -11,89 M -11,96 M -10,03 M -10,22 M
EBITDA — — — — —
R&D Expenses 4,98 M 5,07 M 6,94 M 4,93 M 3,93 M
SG&A Expenses 7,38 M 7,90 M 6,93 M 6,98 M —
D&A 261 679,0 246 791,0 199 266,0 118 620,0 80 748,0
Interest Expense — — — 3 053,0 -3 053,0
Income Tax — — — — -271 122,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 10,79 M 5,37 M 8,10 M 12,82 M 7,94 M
Total Liabilities 3,71 M 4,55 M 1,85 M 3,22 M 1,38 M
Shareholders' Equity 7,07 M 822 013,0 6,25 M 9,60 M 6,55 M
Total Debt — — — — 1,01 M
Cash & Equivalents 6,57 M 1,46 M 5,32 M 8,16 M 6,90 M
Current Assets 10,23 M 4,63 M 7,31 M 12,18 M 7,29 M
Current Liabilities 2,30 M 2,21 M 1,79 M 3,10 M 1,18 M